OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Lung cancer in China: current and prospect	179
Models of supportive care in oncology	47
BRAF mutations in thyroid cancer	42
Viral strategies for circumventing p53: the case of severe acute respiratory syndrome coronavirus	33
Malignant pleural mesothelioma: recent developments	32
Current emerging MRI tools for radionecrosis and pseudoprogression diagnosis	29
Sinonasal cancers treatments: state of the art	24
T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities	24
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer	22
Targeting SUMOylation in cancer	22
The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma	19
Management of epilepsy in brain tumor patients	18
Updated concepts in treatment of giant cell tumor of bone	18
MEK inhibitors in RASopathies	18
Targeted radionuclide therapy: an emerging field in solid tumours	17
Immunotherapy and breast cancer: an overview	17
Next-generation sequencing for the management of sarcomas with no known driver mutations	16
Geriatric assessments and frailty scores in multiple myeloma patients: a needed tool for individualized treatment?	16
Adjuvant therapy of operable nonsmall cell lung cancer: an update	14
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?	14
The role of the tumor matrix environment in progression of head and neck cancer	14
Adrenocortical carcinoma: current treatment options	13
Image-guided surgery in oral cancer: toward improved margin control	13
Targeting the methionine−methionine adenosyl transferase 2A−S-adenosyl methionine axis for cancer therapy	13
The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together	13

Lifestyle and quality of life in patients with early-stage breast cancer receiving adjuvant endocrine therapy	13
Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program	13
Interventions addressing fear of cancer recurrence: challenges and future perspectives	12
Harnessing dendritic cells for innovative therapeutic cancer vaccines	12
Novel immunotherapeutic drugs for the treatment of lung cancer	12
Treatment updates on tenosynovial giant cell tumor	12
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA	12
Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment	12
EBV-associated NK and T-cell lymphoid neoplasms	11
Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis	11
Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes	11
An update on adult forms of hereditary pheochromocytomas and paragangliomas	11
Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up	10
New perspectives on targeting RAF, MEK and ERK in melanoma	10
Preoperative immunotherapy for head and neck cancers: state of art	10
Perspectives in pathomics in head and neck cancer	10
Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics	10
Current status of phosphoinotiside-3 kinase inhibitors in blood cancers	9
Is less more in the surgical treatment of early-stage cervical cancer?	9
Immunomodulation for hepatocellular carcinoma therapy: current challenges	9
Recent advances in primary resistance mechanisms against immune checkpoint inhibitors	9
Epigenetic focus on angioimmunoblastic T-cell lymphoma: pathogenesis and treatment	9
Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia	8
Understanding the tumor-immune microenvironment in prostate cancer	8
Prognostic factors in primary central nervous system lymphoma	8
New molecular entities of soft tissue and bone tumors	8
Desmoid tumors: who, when and how to treat?	8
Biomarkers and immunotherapy: where are we?	8
Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy	8
Anaplastic thyroid carcinoma: advances in molecular profiling and targeted therapy	8
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations	7
COVID-19 and supportive cancer care: key issues and opportunities	7
Bacterial infection-driven lymphomagenesis	7
Lung cancer screening: a critical appraisal	7
Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics	7
The road to chemotherapy-free treatment in chronic lymphocytic leukaemia	7
Adjuvant and neoadjuvant approaches in pancreatic cancer	7
Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer	7
Mutational burden and immune recognition of gliomas	7
Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancer	7
Emerging systemic antitarget treatment for differentiated thyroid carcinoma	6
Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment	6
Current treatments of medulloblastoma	6
Transcriptional and epigenetic control of early life cell fate decisions	6
Targeting cancer stem cell pathways for lung cancer therapy	6
Renal oncocytoma: a challenging diagnosis	6
The role of autologous stem-cell transplantation in multiple myeloma in 2021	6
Supportive care for new cancer therapies	6
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification	6
Challenges adopting next-generation sequencing in community oncology practice	6

New imaging modalities to distinguish rare uterine mesenchymal cancers from benign uterine lesions	6
Desmoid-type fibromatosis: toward a holistic management	6
Hairy cell leukemia: a brief update on current knowledge and treatment prospects	6
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?	6
Content features and its implementation in novel app-based psycho-oncological interventions for cancer survivors: a narrative review	6
Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019–2021	5
Angiogenesis inhibition in lung cancer: emerging novel strategies	5
New perspectives in liquid biopsy for glioma patients	5
Ten steps to establish a national centre for gestational trophoblastic disease	5
Question prompt lists to improve communication between cancer patients and healthcare professionals	5
Advances in myelodysplastic syndrome	5
The multiple molecular dimensions of long noncoding RNAs that regulate gene expression and tumorigenesis	5
Ovarian preservation in gynecologic oncology: current indications and techniques	5
A challenging frontier – the genomics and therapeutics of nonclear cell renal cell carcinoma	5
Educational needs of self-care in cachectic cancer patients and caregivers	5
Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal	5
The evolving treatment landscape of advanced urothelial carcinoma	5
Immunotherapy of sarcomas with modified T cells	5
Psycho-oncology interventions focusing on fatigue and sleep disturbances	5
A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?	5
The role of next-generation sequencing in acute myeloid leukemia	5
Tropomyosin receptor kinases in sarcomas – of joy and despair	5
Artificial intelligence: opportunities in lung cancer	5
Immunotherapy combinations in advanced nonsmall cell lung cancer	5